News

By combining CapellaBio’s SMarTR computational analysis platform with SCT’s iPSC-derived cardiomyocyte discovery platform, advanced drug leads have been identified in the first of a series of programs. Cancer

The study met its primary endpoint of improving progression-free survival (PFS) compared with dacarbazine treatment. The median PFS on the binimetinib arm was 2.8 months versus 1.5 months

Arsia and Biogen will focus on providing meaningful treatment administration improvements for hemophilia patients by enabling subcutaneous versions of treatments that are currently administered via intravenous infusion. The

Basaglar is indicated to improve glycemic control in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is considered as a biosimilar

The agency has set 15 June 2016 as the action date for Vaxchora BLA. If approved, it would become the only anti-cholera vaccine in the US. PaxVax’s BLA

The company has forged an alliance with Chinese biologics firm WuXi AppTec to produce new biological drugs in the country. AstraZeneca has the option to acquire WuXi AppTec’s

Data from the trial further revealed that KIT-302 was more efficacious at reducing hypertension than the widely used hypertension drug amlodipine besylate. Kitov plans to file its New

The study, which will evaluate the safety and clinical efficacy of CAM2038 weekly and monthly injections, is a part of the pivotal registration program for which the companies

The drug was already approved for use in boys aged 9 to 15, and for girls and young women aged 9 to 26. Gardasil 9 is indicated to